GlassScriptPhysician profile
Mona S Shah
NPI 1609087543
$4,369.37
in general payments reported to CMS, 2019-2025
31 companies · $746 in 2025
The $746 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $513 · 2021: $574 · 2022: $351 · 2023: $150 · 2024: $626 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $706.71 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $463.82 | 2019-2023 | Xarelto |
| Amgen INC. | $366.28 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $312.24 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $228.17 | 2019-2020 | |
| Abbvie INC. | $210.24 | 2021-2025 | |
| Covidien LP | $186.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $182.93 | 2019 | |
| Abbott Laboratories | $168.37 | 2022-2025 | Freestyle Libre 3 |
| Scilex Pharmaceuticals INC. | $155.64 | 2019-2025 | Ztlido |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $147.83 | 2022-2024 | Camzyos |
| Ironwood Pharmaceuticals, INC | $143.32 | 2019-2024 | |
| Lilly USA, LLC | $132.52 | 2019-2024 | Mounjaro, Zepbound |
| Radius Health, INC. | $114.30 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $112.49 | 2021-2025 | |
| Esperion Therapeutics, INC. | $100.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.47 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $72.39 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.43 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $33.85 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $33.10 | 2025 | Voquezna |
| Astellas Pharma US INC | $32.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.74 | 2022 | |
| Allergan, INC. | $23.67 | 2019 | |
| Shield Therapeutics INC | $22.93 | 2025 | |
| Genentech USA, INC. | $20.04 | 2020 | |
| Alfasigma USA, INC. | $16.51 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.50 | 2023 | Nuedexta |
| Glaxosmithkline, LLC. | $15.56 | 2019 | |
| Horizon Therapeutics Plc | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.